Brief: Satsuma Pharmaceuticals Announces FDA Acceptance Of 505(B)(2) NDA For Sts101, A Novel And Investigational Dihydroergotamine Nasal Powder Product For The Acute Treatment Of Migraine

Shin Nippon Biomedical Laboratories

18/05/2023 21:22

May 18 (Reuters) - Shin Nippon Biomedical Laboratories
Ltd  2395.T :
    * SATSUMA PHARMACEUTICALS ANNOUNCES FDA ACCEPTANCE OF
505(B)(2)
NDA FOR STS101, A NOVEL AND INVESTIGATIONAL DIHYDROERGOTAMINE
(DHE) NASAL POWDER PRODUCT FOR THE ACUTE TREATMENT OF MIGRAINE
    * SATSUMA PHARMACEUTICALS ANNOUNCES FDA ACCEPTANCE OF
505(B)(2)
NDA FOR STS101, A NOVEL AND INVESTIGATIONAL DIHYDROERGOTAMINE
(DHE) NASAL POWDER PRODUCT FOR ACUTE TREATMENT OF MIGRAINE
    * SATSUMA PHARMACEUTICALS INC: JANUARY 2024 PDUFA DATE
EXPECTED

Source text for Eikon:  ID:nGNX2bBgNS 
Further company coverage:  2395.T 

 ((Reutersbriefs@thomsonreuters.com;))